YolTech Therapeutics

News

Recent biotech financings include big rounds for Lila Sciences, Odyssey, and Ollin, with ARTHEx, Dualitas, and YolTech also in on the action.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.